Bookmark and Share

Vu H. Duong

Vu H. Duong M.D.

Academic Title: Assistant Professor
Primary Appointment: Medicine
Location: UMMC S9D04B
Phone: 410-328-2567
Fax: 410-328-6896

Personal History:

Dr. Duong received his M.D. degree from the University of Virginia in 2005. He stayed in Charlottesville and completed his internal medicine internship and residency at the University of Virginia, followed by a fellowship in hematology/medical oncology at the H. Lee Moffitt Cancer Center at the University of South Florida. During his fellowship, he also finished a Master's degree in clinical and translational research. He developed an interest in myeloid malignancies during his fellowship and joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in August 2012 upon completion of his training.

Research Interests:

Dr. Duong is a clinical researcher primarily interested in developing novel drugs in myelodysplastic syndrome. Few FDA-approved treatment options are currently available for this disease, and Dr. Duong is working on early-phase clinical trials testing new targeted agents for patients who have failed standard therapies.

Clinical Speciality:

  • Myelodysplastic syndromes
  • Acute myeloid leukemia
  • Myeloproliferative neoplasms


Lancet JE, Duong VH, Winton EF, Stuart RK, Burton MK, Zhang S, Cubitt DL, Blaskovish MA, Wright JJ, Sebti SM, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clinical Cancer Research, 2011 March 1; 17(5):1140-6, PMID: 21233404.

Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Therapeutic Advances in Hematology, 2012 April; 3(2): 105-16, PMID: 23556117.

Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leukemia Research, 2013 March; 37(3):300-4, PMID: 23273539.

Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leukemia Research, 2013 May; 37(5):510-5, PMID: 23332452.

Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice? Expert Review of Hematology, 2013 October; 6(5):485-7, PMID: 24083503.

Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clinical Lymphoma, Myeloma, & Leukemia, 2013 Dec;13(6):711-5, PMID: 24054159.

Bhatnagar B, Duong VH, Gourdin TS, Tidwell ML, Chen Q, Ning Y, Emadi A, Sausville EA, Baer MR. Ten-day decitabine as initial therapy for newly diagnosed acute myeloid leukemia patients unfit for intensive chemotherapy. Leukemia & Lymphoma, 2013 Oct 21 [Epub ahead of print] PMID: 24144313.

Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, Cytarabine, Filgrastim, and Mitoxantrone (CLAG-M) Compared to Standard Induction in Acute Myeloid Leukemia from Myelodysplastic Syndrome After Azanucleoside Failure. Leukemia Research, 2013 Dec 25, [Epub ahead of print] PMID: 24439565.